TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06455761
Drug: 68Ga-DOTA-NI-FAPI04
Normalized name: 68Ga-DOTATATE
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-DOTA-NI-FAPI04. Tracer doses of 68Ga-DOTA-NI-FAPI04 will be used to detect tumors by PET/CT.
Study: NCT06062823
Drug: Afatinib 40 MG
Normalized name: afatinib 40 MG
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib 40mg administered orally daily.
Study: NCT00002125
Drug: Foscarnet sodium
Normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05677919
Drug: Pirtobrutinib
Normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05677919
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06110663
Drug: HS-10241+ Almonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10241 300mg twice daily (BID) combined with Almonertinib 110mg once daily (QD) orally, for every cycle of 21 days until disease progression or other criteria for treatment discontinuation will be met.
Study: NCT06145438
Drug: Dienogest
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug is administered orally at the same time every day
Study: NCT06145438
Drug: Depo Medroxyprogesterone acetate
Normalized name: medroxyprogesterone Injection [Depo-Provera]
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug is injected intramuscularly on the buttock
Study: NCT06145438
Drug: Leuprolide (as Leuprolide Acetate)
Normalized name: leuprolide (as leuprolide acetate)
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug is injected intramuscularly on the buttock
Study: NCT04869358
Drug: Ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab 20 mg s.c. on days 1, 7, 14, week 4 and every 4 weeks thereafter
Study: NCT04806373
Drug: Cathflo Activase
Normalized name: Cathflo Activase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cathflo Activase 4mg in 50ml normal saline given through chest pleural catheter
Study: NCT04806373
Drug: Talc Slurry Pleurodesis
Normalized name: Talc
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Talc, 5 gm in 50 ml Normal Saline given through chest pleural catheter
Study: NCT05722262
Drug: K-001
Normalized name: STK-001
DrugBank: CYNK-001 (DB15722)
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877-ER and CSG452 combination tablet
Study: NCT05751798
Drug: OSE-279 100mg
Normalized name: OSE-2101
DrugBank: OSE-2101 (DB17122)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human IgG4 mAb against PD-1
Study: NCT05751798
Drug: OSE-279 300mg
Normalized name: OSE-2101
DrugBank: OSE-2101 (DB17122)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human IgG4 mAb against PD-1
Study: NCT05751798
Drug: OSE-279 500mg
Normalized name: OSE-2101
DrugBank: OSE-2101 (DB17122)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human IgG4 mAb against PD-1
Study: NCT05926856
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine Green 25mg kit for injection
Study: NCT04481945
Drug: bioceramic sealer
Normalized name: Iocetamic acid
DrugBank: Iocetamic acid (DB09403)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.
Study: NCT04828031
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient with inflammatory bowel disease who have low vitamin D (25(OH)D less than or equal to 25 ng/mL) will take Vitamin D 50,000 IU by mouth every week for 12 weeks. Patients will fill out questionnaires to document disease activity score (HBI or Mayo score and sIBDQ) and have blood and stool samples collected before (Week 0), during (Week 8) and after (Week 12) vitamin D intervention.
Study: NCT04954521
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study
Study: NCT05525351
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Propofol is given via target control pump with typical target effect-site propofol concentration 1-5 ug/mL according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
Study: NCT05525351
Drug: Alfentanil
Normalized name: Alfentanil
DrugBank: Alfentanil (DB00802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0\~1000mcg according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
Study: NCT05525351
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical Dexmedetomidine ranged from 0.5-1 ug/kg/hr according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
Study: NCT06326190
Drug: 177Lu-DOTATATE
Normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 177Lu-DOTATATE
Study: NCT04839744
Drug: TG103 produced by the modified manufacturing process
Normalized name: Glycyrrhiza Glabra Processed Root
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: TG103 (a modified manufacturing process), 15mg, SC
Study: NCT04839744
Drug: TG103 produced by the original manufacturing process
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: TG103 (the original manufacturing process), 15mg, SC
Study: NCT03462810
Drug: cabotegravir, CAB
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: open label investigational product
Study: NCT04864743
Drug: ADVATE
Normalized name: Advate
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose.
Study: NCT05083663
Drug: Hyaluronidase
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: using hyaluronidase as an additive to bupivacaine
Study: NCT05208333
Drug: Albenza 200Mg Tablet
Normalized name: Albenza 200mg Tablet
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Distributing albedazol (Zentel) 200mg at school to parents or guardians, dose 15mg/kg divided into 2 times/day, instructions to take the medicine in full dose, at the right time after meals, for 5 days.~Limiting reinfection: Advice on preventing reinfection
Study: NCT04927884
Drug: Sacituzumab Govitecan-Hziy
Normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Phase 1b:~Dose level 1: Sacituzumab govitecan-hziy (7.5 mg/kg IV) Dose level 2: Sacituzumab govitecan-hziy (10 mg/kg IV) Dose level -1 (if needed): Sacituzumab govitecan-hziy (5.0 mg/kg IV)~Phase 2: Dose based on Phase 1b Recommended Phase 2 Dose (IV)~Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)
Study: NCT04858308
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active control
Study: NCT05597995
Drug: Sodium Tetradecyl Sulfate
Normalized name: Sodium Tetradecyl Sulfate
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subjects epidermoid cysts will be treated with 1.5% sodium tetradecyl sulfate foam
Study: NCT05491343
Drug: MedroxyPROGESTERone Injection [Depo-Provera]
Normalized name: medroxyprogesterone Injection [Depo-Provera]
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The drug-induced endometrial changes would likely to prevent the shedding of endometrium, in turn preventing the exposure of AVM.
Study: NCT05474183
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug
Study: NCT00002223
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002223
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06110663
Drug: Pemetrexed + Cisplatin /Carboplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The standard chemotherapy treatment of cisplatin/carboplatin combined with pemetrexed for 4\~6 cycles (every 3 weeks).~Participants will continue receive pemetrexed monotherapy until disease progression or other criteria for treatment discontinuation will be met.
Study: NCT06551896
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pemigatinib and immune checkpoint inhibitors
Study: NCT06343116
Drug: Nimotuzumab injection
Normalized name: inotuzumab ozogamicin Injection
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab will be administered weekly (dose of nimotuzumab depends on part A) until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
Study: NCT05016518
Drug: Arm I (Propofol group)
Normalized name: IOBENGUANE I 123
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil .
Study: NCT05016518
Drug: Arm II (Remimazolam group)
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam group will be started and maintained total intravenous anesthesia with remimazolam and remifentanil.
Study: NCT06531993
Drug: Pectin
Normalized name: Pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using pectin as tablets 600 mg per day for 6 months
Study: NCT05981742
Drug: Metformin Hydrochloride 500 MG
Normalized name: metformin hydrochloride 500 MG
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Brand name: (Glucophage) Tablets per oral / Twice daily / 90 days duration
Study: NCT05981742
Drug: Cabergoline 0.5 MG
Normalized name: cabergoline 0.5 MG
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brand name: (Pergoline) Tablets per oral / single dose per week / 90 days duration
Study: NCT05981742
Drug: Metformin Hydrochloride 500 MG + Cabergoline 0.5 MG
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metformin Brand name: (Glucophage) Tablets per oral / Twice daily / 90 days duration~Cabergoline Brand name: (Pergoline) Tablets per oral / single dose per week / 90 days duration
Study: NCT06441318
Drug: Povorcitinib
Normalized name: Povorcitinib
DrugBank: Povorcitinib (DB18855)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povorcitinib will be administered at protocol defined dose.
Study: NCT06441318
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin will be administered at protocol defined dose.
Study: NCT05200273
Drug: AK114
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AK114 administered by subcutaneous injection
Study: NCT05306847
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab will be given intravenously at a dose of 200mg every 21 days.
Study: NCT05306847
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
Study: NCT05833126
Drug: Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab
Normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: Oxaliplatin, calcium folinate, 5-FU, Atezolizumab and bevacizumab Procedure: HAIC
Study: NCT04613518
Drug: BMS-986165
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified Dose on Specified Days
Study: NCT05668897
Drug: GST-HG171
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
Study: NCT05664555
Drug: Fluorescein Sodium
Normalized name: Fluorescein Sodium
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Fluorescein Sodium 3mL (300mg) or 1mL (100mg) intravenously prior to fluorescein angiography.
Study: NCT06450223
Drug: Perampanel 12 MG
Normalized name: perampanel 12 MG
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 tablet of Perampanel Tablets 12 mg
Study: NCT04732260
Drug: Letermovir
Normalized name: Letermovir
DrugBank: Letermovir (DB12070)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each patient will receive 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP.~5 women will receive 240 mg. 5 women will receive 480 mg.
Study: NCT05382104
Drug: Maribavir
Normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maribavir single 400 mg tablet under three different food conditions (fasted, low fat/low calorie meal, and high fat/high calorie meal) depending upon the treatment sequence allocation on Day 1 of each treatment period.
Study: NCT06552624
Drug: Magaldrate
Normalized name: Magaldrate
DrugBank: Magaldrate (DB08938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of T drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day
Study: NCT06552624
Drug: Magaldrate
Normalized name: Magaldrate
DrugBank: Magaldrate (DB08938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of R drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day
Study: NCT06464679
Drug: CD19 CAR NK cells
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of CD19 CAR NK cells will infused using the dose-escalation strategy.
Study: NCT06307223
Drug: 30% supramolecular salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients received weekly application of 30% supramolecular salicylic acid for a duration of 8 weeks.
Study: NCT05923918
Drug: Oral Sulfate Tablet 2-Day
Normalized name: Sulfate(2-)
DrugBank: Sulfate ion (DB14546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who are randomized into group active comparative will receive bowel preparation from evening to next morning.
Study: NCT05617664
Drug: desmopressin 120 mcg oral tablets
Normalized name: desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: treatment for three months then will stop
Study: NCT05617664
Drug: Mirabegron 25 MG Oral Tablet, Extended Release
Normalized name: MIRABEGRON 25 mg ORAL TABLET, EXTENDED RELEASE
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment for three months then will stop
Study: NCT05907525
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: To induce anesthesia, remimazolam is continuously infused in a dose of 6mg/kg/hr with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). Maintenance dose of remimazolam is 1mg/kg/hr, up to 2mg/kg/hr, and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg.
Study: NCT05944185
Drug: αPD1-MSLN-CAR T Cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: αPD1-MSLN-CAR T Cells
Study: NCT05907525
Drug: 1% propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To induce anesthesia, 1% propofol 1.5-2.5mg/kg is used with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). After patient loses consciousness, anesthesia is maintained through the inhalation of sevoflurane between 1-2 minimum alveolar concentrations (MAC), and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg.
Study: NCT05819060
Drug: Fuzuloparib Combination with Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For the first 6 patients, if DLT≤33.3%, Fuzuloparib 150mg/bid will be used for follow-up research; if DLT\>33.3%, Fuzuloparib will be used for follow-up research at 100mg/bid; Bevacizumab 7.5mg/kg, d1, Q3W.
Study: NCT00000863
Drug: Sitamaquine
Normalized name: Sitamaquine
DrugBank: Sitamaquine (DB04909)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002424
Drug: L-756423
Normalized name: L
DrugBank: L-756423 (DB02009)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002424
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002424
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002424
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05724342
Drug: rhTNK-tPA Thrombolysis
Normalized name: tPA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhTNK-tPA Thrombolysis
Study: NCT04331288
Drug: PT150
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention 1 includes PT150 with alcohol consumption
Study: NCT06409104
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: will receive 1-2 mgkg-1 propofol injection over 30s followed by of propofol a 0.05 to 0.1 mg /kg/min infusion
Study: NCT05324319
Drug: Ad26COVS1
Normalized name: Ad26COVS1
DrugBank: Janssen COVID-19 Vaccine (DB15857)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterologous vaccination
Study: NCT05324319
Drug: ChAdOx1 SARS2 Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterologous vaccination
Study: NCT05324319
Drug: BNT162B2
Normalized name: BNT162b2 Omicron (KP.2)
DrugBank: BNT162b2 Omicron (KP.2) (DB19415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homologous vaccination
Study: NCT05324319
Drug: mRNA-1273
Normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homologous vaccination
Study: NCT04831034
Drug: 68Ga-FAPI-04
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject receive a single intravenous injection of 68Ga-FAPI-04, and undergo PET/CT scanning within the specified time.
Study: NCT04449965
Drug: Povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This will be performed twice daily for two weeks.
Study: NCT05775601
Drug: 18F-LY3950321
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 millicuries (±1 mCi)
Study: NCT05444582
Drug: Levonorgestrel 52 MG Intrauterine System
Normalized name: levonorgestrel 52 MG Intrauterine System
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eligible participants must be 16-35 years old, meet clinic eligibility for IUD placement, and having a LNG 52 mg IUD placed for either:~Emergency Contraception (had unprotected intercourse in the last 5 days) OR Same-day start - \>7 days since the onset of last menstrual period and have no report of unprotected intercourse in the last 5 days.
Study: NCT05728736
Drug: Lemborexant 25 mg
DrugBank: Lemborexant (DB11951)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lemborexant 25mg will be taken nightly for two consecutive nights.